These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 2828537)

  • 1. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    Knoll J
    J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J
    Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.
    Paterson IA; Juorio AV; Berry MD; Zhu MY
    J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
    Engberg G; Elebring T; Nissbrandt H
    J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
    Knoll J
    J Neural Transm Suppl; 1993; 40():69-91. PubMed ID: 8294902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.
    Zsilla G; Földi P; Held G; Székely AM; Knoll J
    Pol J Pharmacol Pharm; 1986; 38(1):57-67. PubMed ID: 3020531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons.
    Demarest KT; Smith DJ; Azzaro AJ
    J Pharmacol Exp Ther; 1980 Nov; 215(2):461-8. PubMed ID: 7441510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition.
    Harsing LG; Magyar K; Tekes K; Vizi ES; Knoll J
    Pol J Pharmacol Pharm; 1979; 31(4):297-307. PubMed ID: 523338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
    Knoll J
    Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trace amines inhibit the electrically evoked release of [3H]acetylcholine from slices of rat striatum in the presence of pargyline: similarities between beta-phenylethylamine and amphetamine.
    Baud P; Arbilla S; Cantrill RC; Scatton B; Langer SZ
    J Pharmacol Exp Ther; 1985 Oct; 235(1):220-9. PubMed ID: 3930699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
    Knoll J; Miklya I
    Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for multiple dopamine receptors involved in the modulation of acetylcholine release in the striatum.
    Hársing LG; Vizi ES
    Pol J Pharmacol Pharm; 1985; 37(3):383-96. PubMed ID: 2866504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
    Knoll J
    J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacology of (-)deprenyl.
    Knoll J
    J Neural Transm Suppl; 1986; 22():75-89. PubMed ID: 3097262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irregular chronic stress related selective presynaptic adaptation of dopaminergic system in rat striatum: effects of (-)deprenyl and amitriptyline.
    Tekes K; Tothfalusi T; Magyar K
    Acta Physiol Pharmacol Bulg; 1986; 12(4):21-8. PubMed ID: 3107343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of selective monoamine oxidase (MAO) inhibitors on conditioned avoidance responses (CAR) of rats.
    Timár J; Knoll B; Gyarmati Z; Knoll J
    Pol J Pharmacol Pharm; 1979; 31(4):251-60. PubMed ID: 523335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The action of (-) deprenyl on monoamine turnover rate in rat brain.
    Zsilla G; Knoll J
    Adv Biochem Psychopharmacol; 1982; 31():211-7. PubMed ID: 6805258
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.